Sanofi’s Tiffany McLamarrah presented “Capitalizing on the Power of Next Generation Gene Editing Using Cas-CLOVER” at 10:00 am on Conference Day 2. This presentation underscores the growing recognition of Cas-CLOVER’s transformative potential in advanced gene editing applications. Sanofi’s adoption and thorough evaluation of Cas-CLOVER provide critical external validation for the platform, particularly in the cell line development and bioprocessing industry, where rigorous standards are paramount.
McLamarrah’s review highlighted key advantages of Cas-CLOVER, including its precision in generating gene knockouts and its compatibility with next-generation sequencing (NGS) and whole genome sequencing (WGS) for detailed characterization. Additionally, the stability of gene knockouts over multiple generations reflects the robustness of Cas-CLOVER, making it an attractive tool for developing gene therapies, biomanufacturing, and other long-term applications.
Sanofi’s commitment to showcasing Cas-CLOVER at this level highlights its confidence in the technology’s ability to streamline research workflows and accelerate therapeutic development. This external validation not only elevates the platform’s credibility but also positions it as a valuable tool for pharmaceutical and biotechnology companies seeking efficient and reliable gene-editing alternatives to CRISPR Cas9.